D. Gibbons

发表

The fibrotic tumor stroma.

M. Yamauchi, T. Barker, D. Gibbons, 2018, The Journal of clinical investigation.

Pan-urologic cancer genomic subtypes that transcend tissue of origin

Michael Ittmann, Chad J Creighton, Yiqun Zhang, 2017, Nature Communications.

Multistep Regulation of Membrane Insertion of the Fusion Peptide of Semliki Forest Virus

D. Gibbons, M. Liao, R. Cheng, 2004, Journal of Virology.

Conformational change and protein–protein interactions of the fusion protein of Semliki Forest virus

J. Lepault, F. Rey, D. Gibbons, 2004, Nature.

Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

R. Perez-soler, D. Gibbons, A. Quintás-Cardama, 2011, The New England journal of medicine.

The rise and fall of gatekeeper mutations? The BCR‐ABL1 T315I paradigm

H. Kantarjian, D. Gibbons, J. Cortes, 2012, Cancer.

Hydrophobic Surfaces That Are Hidden in Chaperonin Cpn60 Can Be Exposed by Formation of Assembly-Competent Monomers or by Ionic Perturbation of the Oligomer (*)

D. Gibbons, P. Horowitz, S. Hua, 1995, The Journal of Biological Chemistry.

Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor γ2 Expression

Yanan Yang, Young-Ho Ahn, Elizabeth J. Goldsmith, 2011, Molecular and Cellular Biology.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Ryan Emerson, Jaime Rodriguez-Canales, Boris Sepesi, 2017, Cancer discovery.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

J. Fujimoto, I. Wistuba, S. Swisher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.

S. Swisher, J. Heymach, D. Gibbons, 2021, Lung cancer.

Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC).

J. Lee, S. Swisher, J. Heymach, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Boris Sepesi, Ignacio I. Wistuba, John V. Heymach, 2018, Journal of Immunotherapy for Cancer.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

I. Wistuba, S. Swisher, J. Heymach, 2019, Journal of Clinical Oncology.

Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis

D. Gibbons, Rakhee Bajaj, Amanda N. Warner, 2022, Cells.

Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis.

R. Derynck, M. Yamauchi, D. Gibbons, 2017, The Journal of clinical investigation.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ultrahigh-throughput Generation and Characterization of Cellular Aggregates in Laser-ablated Microwells of Poly(dimethylsiloxane).

D. Gibbons, Jordan S. Miller, M. Farach-Carson, 2016, RSC advances.

Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.

Joe Y. Chang, P. Thall, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical trials for stem cell therapies

D. Gibbons, A. Trounson, R. Thakar, 2011, BMC medicine.

Developing a case study model for successful translation of stem cell therapies.

D. Gibbons, A. Trounson, P. Tekamp-Olson, 2010, Cell stem cell.

A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow.

L. Byers, D. Gibbons, 2014, Cancer discovery.

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

P. A. Futreal, Xin Hu, I. Wistuba, 2021, medRxiv.

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival

Xin Hu, Jing Wang, Roman K. Thomas, 2020, bioRxiv.

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

D. Gibbons, B. Sepesi, T. Cascone, 2020, Translational lung cancer research.

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Mark M. Davis, P. A. Futreal, R. Emerson, 2020, Nature Communications.

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

J. Roth, J. Lee, S. Swisher, 2022, JAMA network open.

miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1

Diane D. Liu, C. Creighton, J. Heymach, 2010, Molecular Cancer Research.

ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis

K. J. Grande-Allen, Jing Wang, I. Wistuba, 2016, Oncogene.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

I. Wistuba, J. Lee, S. Swisher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity

P. A. Futreal, A. Lucas, Xin Hu, 2020, Genome Biology.

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC): Topic: Translational Research and Biomarkers

I. Wistuba, P. Sharma, J. Heymach, 2017 .

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network

Jiang Yu, Lixia Diao, Jing Wang, 2018, The Journal of clinical investigation.

CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

I. Wistuba, J. Lee, J. Heymach, 2021, Cancer Immunology, Immunotherapy.

OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues

R. Emerson, M. Vignali, I. Wistuba, 2017 .

Association of the T-cell receptor landscape with survival in non-small cell lung cancer.

Xifeng Wu, I. Wistuba, J. Lee, 2018 .

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

J. Heymach, A. Tsao, L. Byers, 2022, Cancer cell.

Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma

Jing Wang, M. McArthur, J. Heymach, 2020, Cancer Prevention Research.

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.

J. Huse, I. Wistuba, A. Reuben, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.

P. Scheet, I. Wistuba, S. Swisher, 2022, Lung cancer.

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.

J. Huse, I. Wistuba, J. Lee, 2019 .

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

J. Lee, J. Heymach, D. Gibbons, 2022, Cancers.

Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.

Jing Wang, I. Wistuba, J. Heymach, 2022, JCO clinical cancer informatics.

Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing

Christopher S. Stevenson, L. Tran, P. Scheet, 2020, bioRxiv.

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

J. Heymach, Y. Xi, Q. Wang, 2020, Annals of Oncology.

A collagen glucosyltransferase drives lung adenocarcinoma progression in mice

Mitchell D. Miller, G. Phillips, J. Tainer, 2021, Communications biology.

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy

D. Gibbons, A. Quintás-Cardama, N. Donato, 2014, Proceedings of the National Academy of Sciences.

Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis

D. Gibbons, Ximing Tang, L. Diao, 2022, Cell reports.

The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors

J. Konen, D. Gibbons, Jared J. Fradette, 2019, Cells.

KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Jeffrey S. Morris, Jing Wang, J. Minna, 2020, American journal of cancer research.

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

H. Kantarjian, D. Gibbons, J. Cortes, 2007 .

Molecular Dissection of the Semliki Forest Virus Homotrimer Reveals Two Functionally Distinct Regions of the Fusion Protein

D. Gibbons, M. Kielian, 2002, Journal of Virology.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC).

J. Lee, S. Swisher, J. Heymach, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The mutually regulatory loop of epithelial–mesenchymal transition and immunosuppression in cancer progression

J. Heymach, D. Gibbons, F. X. Qin, 2015, Oncoimmunology.

MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

D. Gibbons, B. L. Rodriguez, 2022, Cell reports. Medicine.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Bene ﬁ t from Immune Checkpoint Blockade than HLA Class I Genotype in Non – Small Cell Lung Cancer

J. Roth, I. Wistuba, J. Lee, 2022 .

Topology of the Na,K-ATPase

D. Gibbons, K. Sweadner, E. Arystarkhova, 1995, The Journal of Biological Chemistry.

EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer

G. Sica, Yibin Kang, S. Ramalingam, 2022, Cell reports.

Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.

Joe Y. Chang, Steven H. Lin, Z. Liao, 2022, Lung cancer.

Abstract

David E. Breen, Alexis B. Carter, Pinky A. Bautista, 2000, European Neuropsychopharmacology.

TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins

Chad J. Creighton, Don L. Gibbons, C. Creighton, 2018, Nature Communications.

Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients

C. Creighton, Yiqun Zhang, D. Gibbons, 2014, International journal of cancer.

Development, characterization, and applications of multi-material stereolithography bioprinting

D. Gibbons, Jordan S. Miller, Jacob L. Albritton, 2021, Scientific Reports.

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer.

J. Roth, J. Lee, P. Gaudreau, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion

Jing Wang, I. Wistuba, C. Behrens, 2020, Nature Communications.

Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer.

M. Yamauchi, D. Gibbons, J. Kurie, 2020, Matrix biology : journal of the International Society for Matrix Biology.

STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype.

Jing Wang, I. Wistuba, C. Behrens, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted Drug Therapy in Pancreatic Cancer

D. Gibbons, R. Wolff, G. Varadhachary, 2008 .

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Jing Wang, I. Wistuba, J. Sage, 2019, Cancer discovery.

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression.

Alexander Pertsemlidis, Gregory J Goodall, Chad J Creighton, 2009, Genes & development.

Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.

D. Gibbons, T. Cascone, Jared J. Fradette, 2021, Cold Spring Harbor perspectives in medicine.

PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

P. Brown, K. Shokat, I. Wistuba, 2020, Science Translational Medicine.

Distinct Biological Roles for the Notch Ligands Jagged-1 and Jagged-2*

J. Minna, L. Girard, C. Creighton, 2009, The Journal of Biological Chemistry.

Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11

C. Creighton, Daniela Pankova, D. Gibbons, 2017, The Journal of clinical investigation.

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS mutant lung cancer

Jing Wang, J. Konen, D. Gibbons, 2021 .

The role of epithelial – mesenchymal transition programming in invasion and metastasis : a clinical perspective

C. Creighton, D. Gibbons, J. Kurie, 2013 .

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan‐cancer survey of epithelial–mesenchymal transition markers across the Cancer Genome Atlas

Chad J Creighton, C. Creighton, D. Gibbons, 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Jaime Rodriguez-Canales, Pan Tong, Kevin R. Coombes, 2015, Clinical Cancer Research.

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

M. Suarez‐Almazor, H. Tawbi, S. Patel, 2022, Nature Communications.

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

Jing Wang, J. Minna, Y. Xi, 2021, Journal of Thoracic Oncology.

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology

Jing Wang, J. Minna, Y. Xi, 2020, bioRxiv.

Deep learning-based prediction of the T cell receptor–antigen binding specificity

John V. Heymach, Yunguan Wang, Tao Wang, 2021, Nature Machine Intelligence.

TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins

C. Creighton, K. Scott, D. Gibbons, 2018, Nature Communications.

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

Jing Wang, Roman K. Thomas, I. Wistuba, 2021, Nature Communications.

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

J. Roth, S. Swisher, V. Miller, 2021, Journal for ImmunoTherapy of Cancer.

Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target.

Jing Wang, J. Roth, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.

I. Wistuba, S. Swisher, Jun Li, 2020, The Annals of thoracic surgery.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Jeffrey T. Chang, Jing Wang, Fei Yang, 2019, Cancers.

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy

J. Roth, S. Swisher, D. Gibbons, 2018, Oncoimmunology.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

P. A. Futreal, G. Mills, K. Hess, 2016, BMC Medicine.

Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

Jing Wang, I. Wistuba, P. Hwu, 2016, Clinical Cancer Research.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Jing Wang, I. Wistuba, C. Creighton, 2018, The Journal of clinical investigation.

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis

D. Gibbons, J. Kurie, A. Nikonova, 2016, Proceedings of the National Academy of Sciences.

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

C. Creighton, D. Gibbons, Dong-Hoon Shin, 2016, Scientific Reports.

In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer

G. Mills, Ken Chen, C. Creighton, 2018, Nature Communications.

ZEB 1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34 a expression

G. Goodall, P. A. Gregory, A. Pertsemlidis, 2018 .

ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression.

G. Goodall, P. A. Gregory, A. Pertsemlidis, 2012, The Journal of clinical investigation.

Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

A. Tsao, D. Gibbons, F. Fossella, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A collagen glucosyltransferase drives lung adenocarcinoma progression in mice

Mitchell D. Miller, G. Phillips, J. Tainer, 2021, Communications Biology.

Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression

Jing Wang, L. Byers, D. Gibbons, 2016, Oncoimmunology.

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression

Lixia Diao, F. Xiao-Feng Qin, Gordon Robertson, 2014, Nature Communications.

Smoking, p53 Mutation, and Lung Cancer

L. Byers, D. Gibbons, J. Kurie, 2014, Molecular Cancer Research.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Yvonne A. Evrard, Michael W. Lloyd, Jeffrey H. Chuang, 2021, Nature Genetics.

Through the open door: Preferential binding of dasatinib to the active form of BCR‐ABL unveiled by in silico experiments

D. Gibbons, A. Quintás-Cardama, E. Laurini, 2013, Molecular oncology.

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

Steven H. Lin, D. Gibbons, M. Routbort, 2023, Nature Communications.

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.

J. Minna, S. Kobayashi, C. Moran, 2023, Cancer cell.

Immunogenomic profiling of lung adenocarcinoma reveals high-grade growth patterns are associated with an immunogenic tumor microenvironment

Jianhua, P. A. Futreal, P. Scheet, 2022, medRxiv.

The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics

P. A. Futreal, Xin Hu, I. Wistuba, 2021, Nature Communications.

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology

Jing Wang, J. Minna, Y. Xi, 2021, Journal of Thoracic Oncology.

Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients

P. Scheet, J. Minna, I. Wistuba, 2021, Cancers.

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Jing Wang, L. Byers, D. Gibbons, 2020, Molecular Cancer Research.

Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing

L. Tran, P. Scheet, I. Wistuba, 2020, bioRxiv.

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

E. Dmitrovsky, Jing Wang, U. McDermott, 2020, Science Translational Medicine.

Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.

I. Wistuba, C. Creighton, J. Lee, 2020, Clinical lung cancer.

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology

Jing Wang, J. Minna, Y. Xi, 2020, bioRxiv.

Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.

J. Lee, P. Gaudreau, D. Gibbons, 2020, Clinical lung cancer.

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.

E. Dmitrovsky, Jing Wang, I. Wistuba, 2018, Cancer discovery.

Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.

S. Swisher, D. Gibbons, A. Vaporciyan, 2018, The Annals of thoracic surgery.

Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases

C. Creighton, M. Ittmann, Yiqun Zhang, 2018, Clinical Cancer Research.

Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer

Yiling Lu, Rehan Akbani, Gordon B. Mills, 2016, Oncogene.

MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs

D. Gibbons, Rakhee Bajaj, Jared J. Fradette, 2020, Oncogene.

High-Throughput Functional Validation of Progression Drivers in Lung Adenocarcinoma

K. Scott, D. Gibbons, 2014 .

The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.

G. Goodall, P. A. Gregory, C. Creighton, 2011, The Journal of clinical investigation.

Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma

Dror Berel, Yanan Yang, Ignacio I. Wistuba, 2009, PloS one.

Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer.

Jing Wang, I. Wistuba, D. Gomez, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer

Jing Wang, I. Wistuba, J. Lee, 2020, Cancer Immunology, Immunotherapy.

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Travis J Cohoon, D. Hayes, D. Root, 2013, Cancer discovery.

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

J. Konen, P. Gaudreau, L. Byers, 2021, Nature Communications.

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

Jing Wang, I. Wistuba, L. Byers, 2019, Science Translational Medicine.

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O

Haiyi Jiang, D. Gibbons, L. Chow, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).

D. Gibbons, Dong-Wan Kim, L. Chow, 2015 .

Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.

J. Lee, D. Gibbons, A. Vaporciyan, 2022, Clinical Lung Cancer.

Smoking , p 53 Mutation , and Lung Cancer

L. Byers, D. Gibbons, J. Kurie, 2014 .

A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer

D. Gibbons, Jordan S. Miller, Jacob L. Albritton, 2019, Scientific Reports.

Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients

Jaime Rodriguez-Canales, Humam Kadara, Boris Sepesi, 2016, Clinical Cancer Research.

Fibulin-2 Is a Driver of Malignant Progression in Lung Adenocarcinoma

Diane D. Liu, M. Dickinson, S. Hanash, 2013, PloS one.

A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model.

J. West, D. Gibbons, J. Kurie, 2012, Cancer research.

Dysregulation of Cell Polarity Proteins Synergize with Oncogenes or the Microenvironment to Induce Invasive Behavior in Epithelial Cells

C. Scuoppo, D. Gibbons, J. Kurie, 2012, PloS one.

Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.

S. Hanash, C. Creighton, D. Gibbons, 2011, Cancer research.

The role of MicroRNAs in lung cancer development, progression, and metastasis

D. Gibbons, J. Kurie, Zain H Rizvi, 2011 .

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

Mei Jiang, Jaime Rodriguez-Canales, Ignacio I. Wistuba, 2017, Scientific Reports.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Pan Tong, John V Heymach, Abena B. Redwood, 2017, Cancer research.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

Ying Feng, Pan Tong, Robert J. Cardnell, 2017, Oncotarget.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Li Shen, John V Heymach, Kevin R Coombes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity

Jing Wang, I. Wistuba, C. Creighton, 2021, Cell reports.

A pro-tumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.

C. Creighton, D. Gibbons, J. Kurie, 2020, The Journal of clinical investigation.

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

J. Lee, D. Gomez, J. Welsh, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemical and Image Analysis‐Based Study Shows That Several Immune Checkpoints are Co‐expressed in Non–Small Cell Lung Carcinoma Tumors

I. Wistuba, S. Swisher, Jiexin Zhang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The allergy mediator histamine confers resistanceto immunotherapy in cancer patients via activationof the macrophage histamine receptor H1.

Yuan Zhang, Jun Yao, J. Lee, 2021, Cancer cell.

CD8+ T cells inhibit metastasis and CXCL4 regulates its function

Jeffrey T. Chang, Fei Yang, I. Wistuba, 2021, British Journal of Cancer.

Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Jing Wang, J. Minna, L. Girard, 2015, Clinical Cancer Research.

Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis

D. Gibbons, Mabel Perez-Oquendo, 2022, Cancers.

ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer

C. Creighton, B. Raught, Fengju Chen, 2019, Nature Communications.

ZEB 1 sensitizes lung adenocarcinoma to metastasis suppression by PI 3 K antagonism

I. Wistuba, C. Creighton, Steven H. Lin, 2018 .

A genetic cell context-dependent role for ZEB1 in lung cancer

Zhifu Sun, Yanan Yang, Ping Yang, 2016, Nature Communications.

ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.

I. Wistuba, C. Creighton, Steven H. Lin, 2014, The Journal of clinical investigation.

Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC.

Jing Wang, J. Roth, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival

Joe Y. Chang, J. Lee, S. Swisher, 2023, JCO precision oncology.

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

N. Ajami, I. Wistuba, J. Lee, 2021, Nature Communications.

277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy

J. Roth, S. Swisher, A. Tsao, 2020, Journal for ImmunoTherapy of Cancer.

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

D. Gibbons, M. Roudier, Dong-Wan Kim, 2020, British Journal of Cancer.

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

A. Tsao, D. Gibbons, F. Fossella, 2021, JCO precision oncology.

Specific roles for lipids in virus fusion and exit. Examples from the alphaviruses.

Y. Lu, D. Gibbons, M. Kielian, 2000, Sub-cellular biochemistry.

The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers

Jing Wang, C. Creighton, L. Byers, 2015, Oncogene.

p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi

C. Creighton, D. Gibbons, J. Kurie, 2021, Science Advances.

Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study

J. Lee, D. Gomez, S. Swisher, 2016, The Lancet. Oncology.

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

P. A. Futreal, Xin Hu, I. Wistuba, 2021, medRxiv.

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort

Jing Wang, I. Wistuba, S. Swisher, 2020, Journal for ImmunoTherapy of Cancer.

Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC

Jing Wang, J. Konen, L. Byers, 2021, Cancer Research.

IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion.

C. Creighton, K. Scott, D. Gibbons, 2020, Oncogene.

Single-cell analysis of human lung epithelia reveals concomitant expression of the SARS-CoV-2 receptor ACE2 with multiple virus receptors and scavengers in alveolar type II cells

P. Scheet, J. Minna, I. Wistuba, 2020, bioRxiv.

OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Tsao, D. Gibbons, J. Kurie, 2018, Journal of Thoracic Oncology.

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Joe Y. Chang, P. Thall, Steven H. Lin, 2020 .

Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC.

I. Wistuba, J. Lee, S. Swisher, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer

I. Wistuba, J. Lee, S. Swisher, 2020, Clinical Cancer Research.

Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.

Jing Wang, I. Wistuba, L. Byers, 2014 .

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

I. Wistuba, J. Lee, A. Tsao, 2020, The oncologist.

Title : Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer

Jing Wang, I. Wistuba, J. Fujimoto, 2022 .

Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma

M. Dickinson, S. Hanash, I. Wistuba, 2015, Molecular Cancer Research.

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes

P. Shah, A. Maitra, J. Roth, 2022, Journal for ImmunoTherapy of Cancer.

Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.

J. Roth, I. Wistuba, S. Swisher, 2022, Lung cancer.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells

S. Hanash, J. Roth, S. Swisher, 2017, Cancer immunology research.

The Fusion Peptide of Semliki Forest Virus Associates with Sterol-Rich Membrane Domains

D. Gibbons, M. Kielian, A. Ahn, 2002, Journal of Virology.

Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through PAQR11

C. Creighton, Daniela Pankova, D. Gibbons, 2016 .

Ligand-induced Conformational Changes in the Apical Domain of the Chaperonin GroEL (*)

D. Gibbons, P. Horowitz, 1996, The Journal of Biological Chemistry.

The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response

Jing Wang, I. Wistuba, C. Creighton, 2022, Genes & development.

Purification and Crystallization Reveal Two Types of Interactions of the Fusion Protein Homotrimer of Semliki Forest Virus

F. Rey, D. Gibbons, M. Vaney, 2004, Journal of Virology.

Formation and Characterization of the Trimeric Form of the Fusion Protein of Semliki Forest Virus

D. Gibbons, M. Kielian, A. Ahn, 2000, Journal of Virology.

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

N. Ajami, Jing Wang, I. Wistuba, 2023, Nature Medicine.

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

I. Wistuba, D. Gibbons, J. Rodriguez-Canales, 2017, Scientific Reports.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<.

D. Gibbons, H. Tran, X. Le, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

J. Lee, S. Swisher, A. Tsao, 2021 .

Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

P. A. Futreal, J. Roth, I. Wistuba, 2019, Journal of Clinical Oncology.

Angiogenesis , Metastasis , and the Cellular Microenvironment miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt 1 / VEGFR 1

Diane D. Liu, C. Creighton, D. Gibbons, 2011 .

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Joe Y. Chang, Sheeba J. Sujit, J. Hazle, 2023, The Lancet. Digital health.

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Jing Wang, J. Konen, P. Gaudreau, 2020, Nature Communications.

Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer

I. Wistuba, Jiexin Zhang, C. Behrens, 2023, Nature communications.

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience

T. Mendoza, S. Faiz, M. Godoy, 2023, The oncologist.

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

J. Konen, C. Bristow, D. Gibbons, 2019, Cancers.

Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial

J. Lee, D. Gomez, S. Swisher, 2018, International Journal of Radiation Oncology*Biology*Physics.

A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC).

I. Wistuba, J. Lee, J. Fujimoto, 2013 .

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Jing Wang, J. Konen, C. Bristow, 2021, JCI insight.

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

S. Digumarthy, G. Scagliotti, L. Landi, 2023, Cancer discovery.

OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study

J. Roth, S. Swisher, A. Tsao, 2019, Journal of Thoracic Oncology.

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance

J. Konen, D. Gibbons, L. Solis, 2023, Frontiers in Immunology.

Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.

Jing Wang, J. Roth, S. Swisher, 2020, Lung cancer.

Targeting CD38 to improve anti-PD-1/CTLA-4 combination therapy in lung cancer.

Y. Li, D. Gibbons, Limo Chen, 2018 .

ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis

D. Gibbons, Yanhua Tian, B. L. Rodriguez, 2023, Molecular cancer research : MCR.

Archival single-cell genomics reveals persistent subclones during DCIS progression

P. Kristel, N. Navin, Lorraine M. King, 2023, Cell.

OA19.02 Sex Differences Are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma

I. Wistuba, C. Behrens, C. Moran, 2017 .

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2019, Nature Genetics.

MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Tsao, Limei Hu, D. Gibbons, 2019, Journal of Thoracic Oncology.

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Yvonne A. Evrard, David M. Rocke, Jessica J. Andrews, 2022, NAR cancer.

Phosphorylated nuclear DICER1 promotes open chromatin state and lineage plasticity of AT2 tumor cells in lung adenocarcinomas

D. Gibbons, Swathi Arur, S. Kundu, 2023, Science advances.

T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).

I. Wistuba, S. Swisher, A. Reuben, 2019, Journal of Clinical Oncology.

Visualization of the Target-Membrane-Inserted Fusion Protein of Semliki Forest Virus by Combined Electron Microscopy and Crystallography

J. Lepault, J. Navaza, F. Rey, 2003, Cell.

Surgical Outcomes Following Nivolumab or Nivolumab Plus Ipilimumab In Non-Small Cell Lung Cancer

J. Roth, S. Swisher, A. Tsao, 2022, Journal of Thoracic and Cardiovascular Surgery.

Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma

I. Wistuba, Dan Su, J. Fujimoto, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti–PD-1 resistance in non–small cell lung cancer

J. Konen, I. Wistuba, D. Gibbons, 2023, The Journal of clinical investigation.

Cancer Management and Research Dovepress the Role of Epithelial–mesenchymal Transition Programming in Invasion and Metastasis: a Clinical Perspective

C. Creighton, D. Gibbons, J. Kurie, 2022 .

MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC

L. Byers, D. Gerber, D. Gibbons, 2017 .

450 Increased activity of the ATX/LPA axis diminishes CD8+ T cell cytotoxicity via LPAR5 signaling, driving immune checkpoint blockade resistance in non-small cell lung cancer

J. Konen, D. Gibbons, L. Diao, 2022, Regular and Young Investigator Award Abstracts.

MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer

J. Roth, S. Swisher, S. Mortimer, 2018, Journal of Thoracic Oncology.

CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.

I. Wistuba, X. Qin, L. Byers, 2017 .

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

I. Wistuba, C. Creighton, Xiuping Liu, 2018, The Journal of clinical investigation.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells

S. Hanash, J. Roth, S. Swisher, 2017, Cancer Immunology Research.

Through the open door: Preferential binding of dasatinib to the active form of BCR‐ABL unveiled by in silico experiments

D. Gibbons, E. Laurini, M. Fermeglia, 2013, Molecular Oncology.

Abstract 5028: Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressive immune phenotype

J. Roth, I. Wistuba, Jun Li, 2019, Clinical Research (Excluding Clinical Trials).

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.

D. Gibbons, M. Roudier, M. Marotti, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The fibrotic tumor stroma.

M. Yamauchi, T. Barker, D. Gibbons, 2018, The Journal of clinical investigation.

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

Jing Wang, J. Minna, Y. Xi, 2021, Journal of Thoracic Oncology.

AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages

J. Michalek, D. Gibbons, P. Osmulski, 2023, Cell reports.

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab

M. Suarez‐Almazor, D. Gibbons, M. Abdelrahim, 2023, Frontiers in nephrology.

Adapting Nanopore Sequencing Basecalling Models for Modification Detection via Incremental Learning and Anomaly Detection

Y. Xi, L. Byers, D. Gibbons, 2023, bioRxiv.

Abstract 5316: Check point kinase 1 (Chk1) targeting as a novel therapeutic strategy in small cell lung cancer (SCLC)

Jing Wang, L. Byers, H. Piwnica-Worms, 2015 .

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

D. Gibbons, A. Futreal, A. Vaporciyan, 2024, Frontiers in Oncology.

Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

J. Hazle, J. Siewerdsen, C. Behrens, 2024, Cell reports. Medicine.

Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy

S. Woodman, D. Gibbons, Y. Lou, 2024, Cancers.

P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact: Topic: Molecular Changes

I. Wistuba, D. Gomez, Z. Liao, 2017 .